A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Ontology highlight
ABSTRACT: HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.
DISEASE(S): Ovarian Cancer,Prostatic Neoplasms,Colorectal Cancer,Colorectal Neoplasms,Pancreatic Cancer,Ovarian Neoplasms,Breast Cancer,Prostatic Cancer
PROVIDER: 9330 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA